2024-12-18 - Analysis Report
## Teladoc Health Inc. (TDOC) Stock Report

This report analyzes Teladoc Health Inc. (TDOC), a telehealth company providing virtual care services, based on the provided data.

**1. Performance vs. S&P 500 (VOO):**

Teladoc's cumulative return (-62.88%) significantly underperforms the S&P 500's cumulative return (121.73%).  The difference is a substantial -184.6%, placing it at the 4th percentile of its historical range relative to the S&P 500 (based on the provided relative divergence of 0.4).  The provided CAGR data shows extreme volatility and significant negative returns in recent years.

**2. Recent Price Movement:**

* **Closing Price:** $10.68
* **Last Market Price:** $10.12  (This suggests a recent slight decline)
* **5-Day Moving Average:** $10.496
* **20-Day Moving Average:** $10.6615
* **60-Day Moving Average:** $9.6038

The price is slightly below both the 5-day and 20-day moving averages, indicating a potential short-term downward trend.  It's above the 60-day average, suggesting some longer-term support.  The difference between the last market price and the closing price indicates a recent minor price drop.

**3. Technical Indicators and Expected Return:**

* **RSI (33.58):**  Suggests the stock is currently in oversold territory.
* **PPO (-1.24):**  Indicates bearish momentum.
* **20-Day Relative Divergence Change (-0.1):** Shows a recent short-term downward trend relative to the S&P 500.
* **Expected Return (0.0%):**  The provided data indicates no expected excess return over the S&P 500 for long-term (2+ years) investment at this time.  This is a crucial point highlighting significant underperformance.


**4. Recent Earnings Analysis:**

The provided earnings data reveals a concerning trend:

* **Revenue:** Revenue is relatively stable around $0.64 - $0.66 billion across the reported quarters.  There is no significant growth trend observed.
* **EPS:** EPS is consistently negative and significantly worsened in Q2 2024 (-$4.92) compared to other recent quarters. This represents a substantial negative surprise.  There is no positive EPS reported.

There is no information provided regarding expectations to compare the actual results to. The provided numbers alone show consistent losses.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively flat, while profit margin is consistently high (70-72%), but this is likely misleading due to the negative EPS. High profit margins in the face of negative earnings warrant further investigation into accounting practices.
* **Capital and Profitability:** Equity fluctuates, and Return on Equity (ROE) is consistently negative and extremely low, indicating poor profitability and potentially inefficient use of capital.  The exceptionally large negative ROE in Q2 2024 warrants further examination.

**6. News and Recent Issues:**

No recent news (within the last two days) or analyst opinions are provided.  The lack of this information prevents a complete picture of the current market outlook and sentiment towards TDOC.

**7. Overall Analysis:**

TDOC significantly underperforms the S&P 500, showing a substantial negative cumulative return.  Technical indicators suggest oversold conditions but also bearish momentum.  Recent earnings reveal consistently negative EPS, a worrying trend, and concerningly high profit margins despite overall negative performance.  The lack of recent news and analyst opinions hinders a complete assessment.  The high negative ROE highlights significant issues with capital efficiency and profitability.  Based on the available data, the investment outlook for TDOC is very negative.  Further investigation into the reasons behind the consistently negative EPS and the high profit margins is crucial.  The provided data suggests a high risk investment.

**8. Disclaimer:** This report is based solely on the limited data provided.  It does not constitute financial advice.  Independent research and consultation with a financial advisor are strongly recommended before making any investment decisions.
